GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia
Provided By GlobeNewswire
Last update: Jun 27, 2024
SAN FRANCISCO, CALIFORNIA, June 27, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager, TriKE® platform, today announced FDA clearance of its IND application for GTB-3650, allowing the company to proceed with a Phase 1 clinical trial, which is anticipated to start in second half of 2024.
Read more at globenewswire.comNASDAQ:GTBP (3/7/2025, 8:00:01 PM)
2.44
+0.07 (+2.95%)
Find more stocks in the Stock Screener
GTBP Latest News and Analysis
13 days ago - ChartmillTraders are paying attention to the gapping stocks in Tuesday's session.The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
13 days ago - ChartmillWhat's going on in today's pre-market sessionLet's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session.
